Payment overview · 2025
General Payments
$533.08
31 reported records · 10 companies
Healthcare provider profile · identity verified
Arvindselvan Mohanaselvan, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LOS BANOS, CA · NPI 1316472400
Verified facts
What the public records show
CMS Open Payments records show Arvindselvan Mohanaselvan, M.D. received $533.08 in general payments during 2025 across 31 reported records.
Lilly USA, LLC accounted for 27.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Nurtec Odt, Ozempic, Rybelsus.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Trulicity by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ISENTRESS as an associated drug or biological on 37 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Isentress by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $148.24 | 27.8% | 15 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $145.05 | 27.2% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $68.24 | 12.8% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $44.69 | 8.4% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $38.47 | 7.2% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.73 | 4.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.59 | 3.3% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.41 | 3.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.81 | 3.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.85 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $533.08 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $127.63 | 13 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $112.52 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $94.08 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $68.24 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $68.24 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $44.69 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $38.47 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $32.53 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.73 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.59 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.59 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.41 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.85 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $10.45 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $10.16 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 55 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 163 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 159 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
55 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
163 | 53 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
61 | 14 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | ISENTRESS open payments reported associated product |
CMS Open Payments — General Payments 37 supporting records · 24 recipient NPIs · example record 1238003286 |
Isentress · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
159 | 40 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
137 | 39 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
32 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1215 | 351 |
| Metformin Hcl | Metformin Hcl | 519 | 167 |
| Gabapentin | Gabapentin | 508 | 155 |
| Lisinopril | Lisinopril | 508 | 153 |
| Omeprazole | Omeprazole | 483 | 145 |
| Losartan Potassium | Losartan Potassium | 478 | 150 |
| Hydrochlorothiazide | Hydrochlorothiazide | 469 | 143 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 422 | 74 |
| Levothyroxine Sodium | Levothyroxine Sodium | 409 | 113 |
| Furosemide | Furosemide | 368 | 113 |
| Amlodipine Besylate | Amlodipine Besylate | 355 | 103 |
| Trazodone Hcl | Trazodone Hcl | 273 | 71 |
| Potassium Chloride | Potassium Chloride | 243 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 212 | 67 |
| Metoprolol Tartrate | Metoprolol Tartrate | 199 | 66 |
| Sertraline Hcl | Sertraline Hcl | 199 | 42 |
| Alendronate Sodium | Alendronate Sodium | 195 | 53 |
| Azithromycin | Azithromycin | 189 | 138 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 184 | 69 |
| Zolpidem Tartrate | Zolpidem Tartrate | 184 | 29 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 174 | 56 |
| Jardiance | Empagliflozin | 163 | 53 |
| Donepezil Hcl | Donepezil Hcl | 162 | 42 |
| Lorazepam | Lorazepam | 162 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 160 | 52 |
| Ozempic | Semaglutide | 159 | 40 |
| Eliquis | Apixaban | 137 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 136 | 41 |
| Carvedilol | Carvedilol | 133 | 42 |
| Montelukast Sodium | Montelukast Sodium | 129 | 38 |
| Simvastatin | Simvastatin | 129 | 38 |
| Quetiapine Fumarate | Quetiapine Fumarate | 127 | 24 |
| Glipizide | Glipizide | 126 | 49 |
| Ondansetron Odt | Ondansetron | 122 | 48 |
| Diclofenac Sodium | Diclofenac Sodium | 117 | 50 |
| Tramadol Hcl | Tramadol Hcl | 111 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 105 | 29 |
| Mupirocin | Mupirocin | 104 | 53 |
| Bumetanide | Bumetanide | 103 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 102 | 36 |
| Baclofen | Baclofen | 100 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 100 | 34 |
| Nystatin | Nystatin | 100 | 47 |
| Pregabalin | Pregabalin | 95 | 27 |
| Ibuprofen | Ibuprofen | 94 | 34 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 93 | 27 |
| Famotidine | Famotidine | 90 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 90 | 25 |
| Naproxen | Naproxen | 90 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 86 | 28 |
| Meclizine Hcl | Meclizine Hcl | 86 | 38 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 83 | 62 |
| Alprazolam | Alprazolam | 82 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 82 | 49 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 80 | 52 |
| Methocarbamol | Methocarbamol | 80 | 37 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 77 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 76 | 22 |
| Loperamide | Loperamide Hcl | 71 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 67 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 67 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 66 | 17 |
| Allopurinol | Allopurinol | 64 | 21 |
| Levofloxacin | Levofloxacin | 64 | 50 |
| Xarelto | Rivaroxaban | 62 | 12 |
| Trulicity | Dulaglutide | 61 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 60 | 15 |
| Cephalexin | Cephalexin | 58 | 38 |
| Propranolol Hcl | Propranolol Hcl | 58 | 20 |
| Farxiga | Dapagliflozin Propanediol | 55 | 18 |
| Latanoprost | Latanoprost | 55 | 11 |
| Lovastatin | Lovastatin | 55 | 17 |
| Mirtazapine | Mirtazapine | 54 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 52 | 11 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 50 | 20 |
| Hydrocortisone | Hydrocortisone | 50 | 15 |
| Meloxicam | Meloxicam | 48 | 15 |
| Atenolol | Atenolol | 47 | 16 |
| Finasteride | Finasteride | 46 | 11 |
| Fenofibrate | Fenofibrate | 45 | 16 |
| Rizatriptan | Rizatriptan Benzoate | 45 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | 16 |
| Glimepiride | Glimepiride | 44 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 40 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 30 |
| Erythromycin | Erythromycin Base | 38 | 24 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | suppressed |
| Memantine Hcl | Memantine Hcl | 37 | 13 |
| Aripiprazole | Aripiprazole | 36 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | 12 |
| Midodrine Hcl | Midodrine Hcl | 35 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 35 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Fluconazole | Fluconazole | 33 | 15 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Promethazine-Dm | Promethazine/Dextromethorphan | 33 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Clonazepam | Clonazepam | 32 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 32 | 32 |
| Rybelsus | Semaglutide | 32 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 31 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Nifedipine Er | Nifedipine | 31 | 11 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 30 | 11 |
| Lidocaine | Lidocaine | 30 | suppressed |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 20 |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 27 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 27 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 26 | suppressed |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Nystop | Nystatin | 26 | suppressed |
| Prednisone | Prednisone | 26 | 12 |
| Spironolactone | Spironolactone | 26 | 11 |
| Estradiol | Estradiol | 25 | suppressed |
| Methadone Hcl | Methadone Hcl | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 23 | 16 |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Ketoconazole | Ketoconazole | 23 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 19 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Premarin | Estrogens, Conjugated | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 17 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Klor-Con 10 | Potassium Chloride | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 15 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 14 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Trospium Chloride | Trospium Chloride | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | 11 |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Xtampza Er | Oxycodone Myristate | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Isentress | Raltegravir Potassium | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Pulmicort Flexhaler | Budesonide | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $533.08 · 31 records | Lilly USA, LLC | AIRSUPRA, BREZTRI, CAPVAXIVE, Dexcom G6 Transmitter, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, JARDIANCE, M-M-R II, MOUNJARO, NURTEC ODT, Ozempic, Rybelsus, The Cologuard Plus Collection Kit, VAXNEUVANCE, Veozah, XIFAXAN, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error